IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix
This article was originally published in The Pink Sheet Daily
The preliminary evaluation now goes to Germany’s Federal Joint Committee to make a final decision on the products’ usefulness in the country’s health care system, and their future pricing.
You may also be interested in...
Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.